AU6266899A - Methods for producing human tumor antigen specific antibodies - Google Patents

Methods for producing human tumor antigen specific antibodies

Info

Publication number
AU6266899A
AU6266899A AU62668/99A AU6266899A AU6266899A AU 6266899 A AU6266899 A AU 6266899A AU 62668/99 A AU62668/99 A AU 62668/99A AU 6266899 A AU6266899 A AU 6266899A AU 6266899 A AU6266899 A AU 6266899A
Authority
AU
Australia
Prior art keywords
methods
specific antibodies
tumor antigen
human tumor
antigen specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62668/99A
Inventor
Michael Pfreundschuh
Ugur Sahin
Ozlem Tureci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of AU6266899A publication Critical patent/AU6266899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU62668/99A 1998-10-05 1999-09-28 Methods for producing human tumor antigen specific antibodies Abandoned AU6266899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10314098P 1998-10-05 1998-10-05
US60103140 1998-10-05
PCT/US1999/022314 WO2000020460A1 (en) 1998-10-05 1999-09-28 Methods for producing human tumor antigen specific antibodies

Publications (1)

Publication Number Publication Date
AU6266899A true AU6266899A (en) 2000-04-26

Family

ID=22293605

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62668/99A Abandoned AU6266899A (en) 1998-10-05 1999-09-28 Methods for producing human tumor antigen specific antibodies

Country Status (3)

Country Link
EP (1) EP1117691A1 (en)
AU (1) AU6266899A (en)
WO (1) WO2000020460A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
AT411262B (en) * 2001-09-27 2003-11-25 Wolff Klaus Dr HUMAN ENDOGENIC RETROVIRUS
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
JP5314242B2 (en) 2004-04-27 2013-10-16 中外製薬株式会社 Plasma cell growth method
FR2890859B1 (en) * 2005-09-21 2012-12-21 Oreal DOUBLE-STRANDED RNA OLIGONUCLEOTIDE INHIBITING TYROSINASE EXPRESSION
CA2680914C (en) * 2007-03-13 2019-06-18 University Of Zurich Monoclonal human tumor-specific antibody
US8715743B2 (en) 2007-08-03 2014-05-06 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
WO2009147864A1 (en) * 2008-06-04 2009-12-10 静岡県 Method for analysis/identification of antibody gene at one-cell level
CN101885758B (en) * 2009-05-11 2014-04-30 中国医学科学院肿瘤研究所 Auto-antigen epitope and encoding gene and application thereof
EP2714742A1 (en) * 2011-06-03 2014-04-09 CT Atlantic Ltd. Magea3 binding antibodies
US20140287402A1 (en) * 2011-06-27 2014-09-25 Valneva Method for screening cells
WO2016201304A1 (en) 2015-06-10 2016-12-15 Nantkwest, Inc. Modified nk-92 cells for treating cancer
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
CA3036713A1 (en) 2016-09-29 2018-04-05 Nantkwest, Inc. Hla class i-deficient nk-92 cells with decreased immunogenicity
AU2018206401B2 (en) 2017-01-06 2022-07-21 Immunitybio, Inc. Genetically modified NK-92 cells with decreased CD96/TIGIT expression
EP3703735A1 (en) 2017-11-01 2020-09-09 Nantkwest, Inc. Nk-92 cells to stimulate anti-cancer vaccine
DE112019000608B4 (en) 2018-01-31 2021-05-06 Nantkwest, Inc. USE OF 5% HUMAN ALBUMIN IN WASHING AND HARVESTING MEDIA
WO2019177986A1 (en) 2018-03-12 2019-09-19 Nantkwest, Inc. Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
US20210198342A1 (en) 2018-05-22 2021-07-01 Nantkwest, Inc. FC-EPSILON CAR (Very imp commercially - in clinical trial)
JP7208262B2 (en) 2018-05-22 2023-01-18 イミュニティーバイオ インコーポレイテッド Methods for Optimizing NK-92 Cell Growth Using Poloxamers
WO2019226521A1 (en) 2018-05-22 2019-11-28 Nantkwest, Inc. Basal media for growing nk-92 cells
US20210267190A1 (en) 2018-07-10 2021-09-02 Nantkwest, Inc. Cryopreservation
EP3820994A1 (en) 2018-07-10 2021-05-19 Nantkwest, Inc. Generating cik nkt cells from cord blood
US20210293787A1 (en) 2018-08-01 2021-09-23 Nantkwest, Inc. Combined invasion and cytotoxicity assay using chemokine secreting target cells
US10960024B2 (en) 2018-08-01 2021-03-30 Nantkwest, Inc. Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
JP2021531808A (en) 2018-08-01 2021-11-25 イミュニティーバイオ インコーポレイテッド Chemokine-responsive activated natural killer cells with demonstrated secondary homing activation
JP7536649B2 (en) 2018-11-06 2024-08-20 イミュニティーバイオ、インコーポレイテッド Chimeric antigen receptor modified NK-92 cells
AU2019388876A1 (en) 2018-11-26 2021-05-20 Immunitybio, Inc. IL-2 Dependent NK-92 cells with stable Fc receptor expression
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2023081163A1 (en) 2021-11-02 2023-05-11 Immunitybio, Inc. Natural killer cells for chordoma therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011507A2 (en) * 1992-11-19 1994-05-26 Gingeras Thomas R Production of monoclonal recombinant antibodies without the use of hybridomas by in vitro spleen fragment culture combined with isothermal self-sustained sequence replication of rna

Also Published As

Publication number Publication date
EP1117691A1 (en) 2001-07-25
WO2000020460A1 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
AU6266899A (en) Methods for producing human tumor antigen specific antibodies
AU1462300A (en) Human pan-hcv human monoclonal antibodies
AU1704099A (en) Monoclonal human natural antibodies
TWI365193B (en) Human antibodies that bind human il-12 and methods for producing
ZA9810130B (en) Tumor-specific antigens methods for their production and their use for imunization and diagnosis
AU5686698A (en) Methods for the production of chicken monoclonal antibodies
AU2948199A (en) Breast cancer antigen
WO2001030393A8 (en) Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
AU9374198A (en) Methods for producing human antibodies in scid mice using dendritic cells
EP0977590A4 (en) Human monoclonal antibodies
AU7572198A (en) Tumor-associated antigen
AU2452301A (en) Protein methylarginine-specific antibodies
GB9804065D0 (en) Tumour associated antigen 791Tgp72
AU5046700A (en) Diagnostic monoclonal antibody for LTiGTyersinia pestisLT/iGT
ZA941645B (en) Antibodies specifically reactive against human prostate specific antigen.
AU3416599A (en) Casb414: antigen overexpressed in several tumors
AU2001245552A1 (en) Transcutaneous immunization for large particulate antigens
AU1809695A (en) Tumor associated monoclonal antibody 123av16
AU7128098A (en) Methods of obtaining antigens specific for fungi, antibodies for such antigens, and diagnosis of disease using such antigens and/or antibodies
AU2169797A (en) Improved production of antibodies through the use of antigen antibody complexes
AU4775899A (en) Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production
EP1446416A4 (en) Tumor specific monoclonal antibodies
AU1370300A (en) Antigen-binding fragments specific for tumor associated antigens
AU1443900A (en) Glycoprotein antigens, antibodies specific thereto and method for producing same
AU2004205174B2 (en) 36P6D5: Secreted tumor antigen

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase